Anaphylm Therapeutic Specialist – Launch Role

Aquestive Therapeutics, Inc.; Baltimore (MD); On-site; USD 125,000 - 150,000; Full time

Benefits offered by this job

Bonus eligibility

Health insurance

Retirement benefits

Paid holidays and vacation

Sick days

Job summary

Aquestive Therapeutics, Inc. in Baltimore, MD is seeking a Therapeutic Specialty Representative to launch Anaphylm, educate providers, and build trusted relationships with healthcare stakeholders. This role emphasizes strategic territory planning, payer navigation, and compliant promotion in a fast-paced launch environment.

You will partner with regional teams, manage key accounts, and deliver clinical education while maintaining CRM excellence and adherence to PDMA guidelines.

Qualifications

• Bachelor's degree required.
• 3+ years of pharmaceutical, specialty, or B2B sales with a proven track record.
• Deep understanding of payer coverage and prior authorization workflows.
• Willingness to travel up to 50% for meetings and conferences.

Responsibilities

• Design and execute territory business plans to identify high-potential accounts and drive market penetration.
• Deliver compelling, compliant clinical presentations demonstrating Anaphylm's value to providers.
• Master payer coverage dynamics and collaborate with Market Access to overcome authorization barriers.
• Maintain CRM records with call notes, sampling activity, and next steps; ensure PDMA compliance.

Skills

Pharma sales

Payer navigation

Analytical skills

Education

Bachelor's degree

Job description

Aquestive Therapeutics, Inc. in Baltimore, MD is seeking a Therapeutic Specialty Representative to launch Anaphylm, educate providers, and build trusted relationships with healthcare stakeholders. This role emphasizes strategic territory planning, payer navigation, and compliant promotion in a fast-paced launch environment.

You will partner with regional teams, manage key accounts, and deliver clinical education while maintaining CRM excellence and adherence to PDMA guidelines.